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Abstract 
Background: Chromogranin A (CgA) is a valuable biomarker for detection and follow-up of 
patients with neuroendocrine neoplasms (NENs). However, various comorbidities may influence 
serum CgA, which decreases its diagnostic accuracy. We aimed to investigate which laboratory 
parameters are independently associated with increased CgA in real-life setting and to develop a 
scoring system, which could improve the diagnostic accuracy of CgA in detecting patients with 
NENs. 
Methods: This retrospective study included 55 treatment naïve patients with NENs and160 
patients with various comorbidities but without NEN (nonNENs). Scoring system (CgA-score) 
was developed based on z-scores obtained from receiver operating curve analysis for each 
parameter that was associated with elevated serum CgA in nonNENs.  
Results: CgA correlated positively with serum BUN, creatinine, α2-globulin, red-cell 
distribution width, erythrocyte sedimentation rate, plasma glucose and correlated inversely with 
hemoglobin, thrombocytes and serum albumin. Serum CgA was also associated with the 
presence of chronic renal failure, arterial hypertension and diabetes and the use of PPI. In the 
entire study population, CgA showed an area under the curve of 0.656. Aforementioned 
parameters were used to develop a CgA-score. In a cohort of patients with CgA-score <12.0 
(N=87), serum CgA>156.5 ng/ml had 77.8% sensitivity and 91.5% specificity for detecting 
NENs (AUC 0.841, 95% CI 0.713-0.969, P<0.001). Serum CgA had no diagnostic value in 
detecting NENs in patients with CgA-score >12.0 (AUC 0.554, 95% CI 0.405-0.702, P=0.430). 
Conclusions: CgA-score encompasses a wide range of comorbidities and represents a promising 
tool that could improve diagnostic performance of CgA in everyday clinical practice. 
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1. Introduction 
Chromogranin A (CgA) is an acidic glycoprotein and a member of the granin family, which can 
be found in secretory granules of all endocrine and neuroendocrine cells[1]. It has an important 
regulatory role in the process of formation and exocytosis of secretory granules that contain 
various peptide hormones [2]. CgA is secreted along with peptide hormones and metabolized in 
various tissues into biologically active peptides, such as vasostatin, pancreastatin, catestatin and 
serpinins[2]. Some studies suggest that these peptides might be involved in various biological 
processes; however their exact role has not been completely elucidated. For instance, vasostatin 
inhibits a series of effects induced by vascular endothelial growth factor (VEGF) on endothelial 
cells, which may be very important in terms of tumorgenesis[3]. Moreover, evidence exists that 
CgA counteracts the effects of tumor necrosis factor-α (TNF-α) on the endothelial cells, which is 
an important role in the setting of systemic inflammation [4]. Serpinin peptides act as myocardial 
β-adrenergic like agonists that increase the cardiac inotropy and lusitropy. They may also affect 
the cell survival and exert neuroprotective effects [5].  Pancreastatin and catestatin display 
beneficial effects on glucose metabolism, dyslipidemia and arterial hypertension in patients with 
metabolic syndrome [6][7]. It is notable that CgA not only controls exocytosis of secretory 
granules in systemic neuroendocrine response to various disease conditions, but is also a 
molecular precursor of all these peptides. Thus, it is common to find increased CgA serum levels 
in patients with sepsis [8], acute exacerbation of rheumatoid arthritis [9], inflammatory bowel 
disease [10][11], various metastatic malignancies [12], heart and renal failure [13][14], 
complicated myocardial infarction [15], arterial hypertension [16] and chronic atrophic gastritis 
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[17]. Moreover, the use of proton pump inhibitors (PPIs) may also increase CgA serum levels 
[18]. Thus, CgA can be found in every human and its abundance is not per se an indicator of 
neuroendocrine neoplastic disease, but the increase above a normal distribution may indicate the 
presence of  neuroendocrine neoplasm (NEN). 
CgA is routinely used only in the diagnosis and follow-up of patients with NENs [19]. NEN 
tumor cells secrete CgA, which has a diagnostic, predictive and prognostic role in this population 
of patients. CgA has a relatively good predictive accuracy, so the rise of CgA in patients with 
resected NEN is the first sign of recurrence in 85% of patients [20]. Moreover, the short-term 
decrease in serum CgA treated with everolimus, predicts long-term treatment response [21].  
However, due to its non-specific nature, the exact diagnostic accuracy of CgA as a screening 
method in detecting patients with NENs remains controversial. Sensitivity of CgA ranges from 
53% to 85%, while specificity ranges from 84% to 96% in detecting patients with NENs in the 
general population [22]. This greatly differs between studies, depending mainly on the control 
group. Studies focusing on the diagnostic accuracy of CgA may be distinguished to those which 
exclude or include subjects with interfering factors [22]. Studies that used healthy blood donors 
had highest diagnostic accuracy of CgA in detecting NENs, while the diagnostic accuracy 
substantially decreased when control group consisted of patients using PPI or patients with other 
malignant diseases [22]. Moreover, in a study by Marotta V et al. that included 42 subjects 
affected with NEN, 120 subjects affected with non-endocrine neoplasias and 100 non-neoplastic 
subjects affected with benign nodular goiter, serum CgA had no diagnostic value in detecting 
patients with NENs [23]. In addition, the diagnostic accuracy of CgA also depends on the stage 
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of the disease and tumor volume [24,25], primary tumor site [25] and the method of 
measurement [26,27].  
The concept of this study was to find which anthropometric and laboratory parameters are 
associated with increased serum CgA in patients without NEN. In addition, we aimed to deduce 
a scoring system consisting of the relevant of those parameters and hypothesized that this scoring 
system could stratify subjects into cohorts that have different diagnostic accuracy of CgA. Thus, 
the scoring system could potentially select subjects in whom CgA does not have any diagnostic 
accuracy due to their substantial comorbidities and could help to avoid unnecessary costly 
diagnostic work-up. On the other hand, it could also help to select patients in whom increased 
CgA suggests the presence of NEN and thus warrants further investigation. 
 
2. Patients and methods 
2.1. Patients 
This single-center retrospective study was performed in a tertiary referral center for patients with 
NEN at University hospital center Sisters of charity, Zagreb, Croatia and included all patients in 
whom serum CgA was measured between 2012 and 2016.  Medical charts from patients were 
retrieved and analyzed by physicians with clinical expertise in diagnosis and treatment of 
patients with NEN. Initially, we included all patients for whom more than 90% of analyzed 
variables were available at the time when CgA was measured. In patients who had several CgA 
measurements, only clinical and laboratory parameters during the first CgA measurement were 
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included in the final analysis. Repeated measurements of CgA and other laboratory parameters 
were not analyzed. 
The indication for CgA measurement was set by physicians of different specialties in case of 
suspicion of NEN. All subjects with increased CgA were referred to a multidisciplinary NEN 
team and all of them had undergone further diagnostic work up. It included chest x-ray and 
abdominal ultrasound, 24-hour urinary 5-hydroxyindoleacetic acid collections and serum gastrin 
(in patients with suspected pancreatic NEN) in all subjects. Based on the ongoing clinical 
suspicion of a NEN after this initial diagnostic work-up, some patients continued a more specific 
diagnostic process with computed tomography (CT) and/or magnetic resonance imaging (MRI) 
and 99mTc-Tektrotyd scintigraphy and/or  18F-fludeoxyglucose positron emission tomography 
(18F-FDG PET). CT protocols included early arterial phase sequences and MRI protocols 
included both contrast enhanced and diffusion-weighted sequences. All patients with previously 
established diagnosis of NEN, have undergone all aforementioned diagnostic tests. If even after 
this work up, the presence of a NEN could not be demonstrated, these subjects were defined as 
controls (nonNENs). Patients with NENs were included only if they were treatment naïve and 
had active disease at the time of CgA measurement. Patients who underwent curative surgery 
and did not have radiological evidence of recurrence or metastases were excluded from the 
study.   Patients with NEN were classified based on ENETS guidelines of 2012 [28]. Finally, of 
460 CgA measurements, 160 subjects could be included into the control group and 55 subjects 
into the NEN group; a flowchart of the study subjects is presented in figure 1. 
The following anthropometric and the following clinical parameters were recorded in all 
subjects: age, gender, body mass, body height, body mass index, the history of arterial 
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hypertension, diabetes, heart failure, chronic obstructive pulmonary disease, liver cirrhosis, renal 
disease, other malignant disease, gastritis, atrophic gastritis, inflammatory bowel disease, 
autoimmune diseases (other than atrophic gastritis), current infectious disease and current 
malignant disease (besides NEN), recent weight loss (within 3 months prior to CgA 
measurement), smoking and the use of proton pump inhibitors. Active malignant disease was 
defined as newly diagnosed malignant disease (other than NEN), systemic treatment for 
metastatic disease or terminal phase of malignant disease.  
The study was conducted according to the Declaration of Helsinki and approved by the ethics 
committee of the University Hospital Center Sisters of charity. 
 
2.2. Laboratory analyses 
In addition to the anthropometric an clinical parameters the following laboratory values were 
analyzed: complete blood cell count (CBC), erythrocyte sedimentation rate (ESR), red cell 
distribution width (RDW), blood urea nitrogen (BUN), serum creatinine, serum cholesterol, 
high-density lipoprotein (HDL), low-density lipoprotein (LDL), serum triglycerides, serum 
bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-
glutamyltransferase (GGT), lactate dehydrogenase (LDH), fibrinogen, C-reactive protein (CRP), 
protein electrophoresis, prothrombin time (PT), thrombin time (TT), serum amylase, alkaline 
phosphatase (ALP), creatine kinase (CK), serum sodium, potassium, chloride, phosphate, 
calcium, iron, total iron-binding capacity (TIBC), unsaturated iron-binding capacity (UIBC) and 
serum glucose. Parameters analyzed from urine were: urine specific gravity, amylase, calcium, 
creatinine, pH, phosphorus, presence of epithelial cells, erythrocyte and leukocyte count.  All 
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analyses were made with the analytic system on the automatic analyzer AU 2700 (Beckman 40) 
with original chemicals (Beckman Coulter International S. A.). 
CgA level was measured via ELISA using a commercially available kit (Demeditec Diagnostics 
GmbH, Germany) [29]. Blood samples were collected by venipuncture into serum-separator 
tubes without anticoagulant. Serum was separated by centrifugation and immediately stored at 
−20 °C until analysis, which was performed as described in the manufacturer’s instructions. 
Normal range was considered to be 12.5 – 100 μg/L, as provided by the manufacturer. Elevated 
serum CgA was considered > 100 μg/L. 
2.3. Statistical analyses 
Patient characteristics were analyzed with descriptive statistics and presented as a median and 
interquartile range.  Since the majority of parameters did not follow normal distribution we used 
nonparametric tests as follows: independent continuous variables were compared with Mann-
Whitney U test and categorical variables were compared using Fisher's exact test. Receiver 
operating characteristic (ROC) analysis was used to analyze the diagnostic accuracy of CgA in 
the entire study population. Afterwards, Spearman correlation was performed in nonNEN 
patients in order to detect the association between CgA and anthropometric and laboratory 
parameters. Eta statistic was used for correlation between continuous and categorical variables. 
ROC analyses were performed for parameters that showed significant correlation coefficient in 
order to establish a cut-off value for each variable. Variables available in more than 90% of 
controls, which showed significant association with CgA on ROC analysis, were included into 
the CgA scoring system (CgA-score). CgA-score was calculated by multiplying z-scores 
obtained in ROC analysis. Afterwards, the entire study population was divided into five 
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subgroups based on CgA-score values and reassessed the diagnostic accuracy of CgA in each 
subgroup. The results of (ROC) analysis were presented with sensitivity, specificity and positive 
likelihood ratio for each CgA cut-off. Two-tailed P values <0.05 were considered significant. We 
did not perform p-value adjustment for multiple testing, due to hypothesis and primary aim of the 
study. The aim of the correlation analysis was to detect which parameters have the greatest 
impact within the CgA-score, and not to claim the actual strength of these correlations with other 
parameters. Statistical analyses were performed by using SPSS Version 20.0. 
3. Results 
3.1. General characteristics 
The median age of our study population was 56.0 years (41.0-66.0), 97 (45.1%) of them were 
males and median CgA was 88.0 μg/L (38.0-280.0). A total of 102 (47.4%) of subjects had 
serum CgA above the upper reference range value. A median CgA level was lower in nonNEN 
group (Table 1). The presence of atrophic gastritis was higher in NEN group, while the presence 
of infectious diseases was higher in nonNEN group. Five patients had gastric NENs. Three 
patients had G1 and two patients had G2 NENs. All of them were categorized as type 1 gastric 
carcinoids and all had localized disease. Patients with gastric NENs had higher serum CgA levels 
when compared with 10 patients with localized panNENs [197 (130 – 335) vs.  68 (29 – 110) 
ng/ml], but the difference was not statistically significant (P=0.221). There were no significant 
differences in laboratory parameters between nonNEN and NEN group (Supplemental Table 1). 
The presence of all other comorbidities was similar in both groups. Ki67 index was available in 
49 (89.1%) patients. The group of patients with NEN were further subdivided based on Ki67 
index into three groups, patients with G1 NENs had significantly lower CgA level (161.0 [68.0 - 
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466.0] μg/L), compared to G2 (308.0 [29.0-863.0] μg/L) and G3 NENs (357.0 [237.0-1100.0] 
μg/L) (P=0.001). The difference between CgA serum levels between G2 and G3 was not 
statistically significant (P=0.573). Metastatic disease was more prevalent in patients with G3 
NENs (Table 1). In the entire study population, CgA had the area under the curve (AUC) of 
0.656 (95% CI 0.564 - 0.749) (Figure 3). The cut-off value of CgA of 189 μg/L had a sensitivity 
of 56.4% (95% CI 42.3 - 69.7), specificity of 76.9% (95% CI 69.6 - 83.2) and positive predictive 
value of 2.44 (95% CI 1.7-3.5). In a subgroup analysis that included only patients with localized 
NENs and all nonNEN subjects, CgA had no diagnostic value in detecting patients with NENs 
(AUC 0.522, 95% CI 0.392 - 0.652 P=0.710).  
We have also performed a subgroup analysis of patients with nonNEN malignant disease in order 
to evaluate the diagnostic performance of CgA in patients with evident malignant disease. There 
were 21 patients with nonNEN metastatic disease and 27 metastatic NENs. Among 21 patients 
with nonNEN metastatic disease, 16 had adenocarcinoma, 2 melanoma, 1 plasmacytoma and 2 
undefined high-grade carcinomas. CgA was increased above the ULN in 12 (57.1%) patients in 
the nonNEN group and 22 (81.5%) in the NEN group (P=0.095). However, patients with NENs 
had significantly higher CgA levels [117 (35 – 211) vs. 296 (134 – 920), P<0.001]. 
Consequently, the diagnostic accuracy of CgA was substantially better in patients with metastatic 
disease (AUC 0.820, 95% CI 0.698 - 0.941, P<0.001). In this subgroup of patients with nonNEN 
and NEN metastatic disease, CgA of 211.5 μg/L had both a sensitivity and specificity of 81% 
each in detecting patients with NENs.  
 
3.2. Correlation between clinical and biochemical parameters and CgA in 
nonNEN group  
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A total of 66 (41.2%) of nonNEN patients had increased serum CgA. Subjects with increased 
CgA had also lower erythrocyte and thrombocyte count, hemoglobin, MCHC, PT, LDL 
cholesterol, albumins and urinary phosphate levels, but higher alpha2-globulins, BUN and 
creatinine levels when compared with subjects with normal CgA (Supplemental Table 2). CgA 
correlated positively with urinary leukocyte and erythrocyte count, serum BUN and creatinine 
concentration, α2-globulin fraction, RDW, ESR, plasma glucose, previously established 
diagnosis of chronic renal failure, arterial hypertension, diabetes and the use of PPI. CgA was 
inversely associated urinary phosphate, hemoglobin, thrombocyte count, serum albumins and 
body mass. Correlation coefficients for each parameter are presented in table 2 and categorized 
based on the correlation strength. ROC analysis was performed for each of the previously 
mentioned parameter, cut-off values, AUC and z-statistic values are presented in table 2. Only 
parameters that showed statistically significant association with CgA in both Spearman 
correlation and ROC analysis, and parameters available in ≥140 control subjects were included 
into a scoring system (CgA-score). The correlation plots and box-plots were made for these 
variables and presented in figure 2.  
 
3.3. The diagnostic performance of CgA in the entire study population divided by 
CgA-score 
A CgA-score was calculated by multiplying the z-statistic values, which are provided in table 2 
and ranged from 0 to 31.3. There was no significant difference in CgA-score between controls 
and patients with NENs [12.9 (7.6 - 16.8) vs. 13.4 (9.7 - 17.7), P=0.436]. Moreover, there was no 
significant difference in CgA-score between patients with G1, G2 and G3 NENs [ G1 13.8 (11.3 
- 18.7), G2 10.9 (5.1 - 16.0) and G3 14.7 (11.8 - 20.3), P=0.105].  
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A CgA-score cut-off of >12.0 had the highest Youden index in predicting increased serum CgA 
levels with sensitivity of 77.8% and specificity of 75.3% (AUC 0.835, 95% CI 0.766 - 0.905, 
P<0.001) in nonNEN patients. In a cohort of patients with CgA-score <12.0, serum CgA > 156.5 
ng/ml had 77.8% sensitivity and 91.5% specificity for detecting NENs (AUC 0.841, 95% CI 
0.713 - 0.969, P<0.001). On the other hand, serum CgA had no diagnostic value in detecting 
NENs in patients with CgA-score > 12.0 (AUC 0.554, 95% CI 0.405 - 0.702, P=0.430) (Figure 
3). We have also performed a subgroup analysis that included only patients with localized NENs 
and all nonNEN subjects. In this subgroup analysis, patients with CgA-score <12 had the 
diagnostic accuracy of CgA in detecting patients with NENs of 78% (AUC 0.779, 95% CI 0.598 
- 0.959, P=0.008). However, in patients with CgA-score >12, CgA had no diagnostic value in 
detecting localized NENs (AUC 0.397, 95% CI 0.201 - 0.593, P=0.264). 
Further subgroup analysis was performed, when entire study population was arbitrarily divided 
into five subgroups according to the CgA-score: 0-8 (interval [I] 1), 8-12 (I2), 12-16 (I3), 16-22 
(I4) and >22 (I5). AUC for CgA in the entire population was 0.656 and it increased to 0.905 in 
I1, 0.788 in I2 and 0.745 in I4 (Table 3, Figure 4). On the other hand, CgA did not have any 
diagnostic value in subjects with CgA-score in I3 and I5 (Table 3). Patients in I3 had the lowest 
prevalence of metastatic disease. CgA cut-off values were substantially different between the 
groups. Overall, the CgA-score increased the diagnostic accuracy of CgA in detecting patients 
with NENs in 124 (68.9%) subjects. 
 
3.4. Comparison between CgA-score and detailed medical history in increasing 
the diagnostic performance of CgA 
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In order to elucidate the impact of CgA-score in routine clinical setting, we compared the 
change in diagnostic accuracy of CgA in subgroups of patients divided based on CgA-score 
and number of comorbidities that were found to be associated with increased CgA in 
previous studies (arterial hypertension, diabetes, heart failure, liver cirrhosis, renal disease, 
other malignant disease, atrophic gastritis, inflammatory bowel disease and infectious 
disease). Serum CgA correlated positively both with the number of comorbidities (ρ = 0.406, 
P < 0.001) and CgA score (ρ = 0.588, P < 0.001). However, when ROC analysis was 
performed in patients divided into subgroups based on CgA-score intervals and number of 
comorbidities, CgA-score was far more efficient in both increasing and decreasing the 
diagnostic accuracy of CgA in detecting patients with NENs (Figure 5).   
 
4. Discussion 
To the best of our knowledge, this is the first study that has attempted to incorporate all 
comorbidities that may affect serum CgA into a scoring system. Our study showed that the CgA-
score increases the diagnostic accuracy of CgA in detecting patients with NENs, which may be 
useful in routine clinical practice.  
The overall diagnostic accuracy of CgA in our study was 66%, which is similar to recent studies 
assessing the diagnostic accuracy of a novel biomarker - blood-based multi-transcriptome assay 
(NETest) [30,31]. NETest showed excellent diagnostic accuracy when compared with single 
CgA measurement, but due to its high costs and limited availabilities its wide-spread routine use 
in clinical practice is unlikely in the near future.   
As reported previously, we also showed the association of CgA with arterial hypertension, renal 
insufficiency, diabetes and the use of PPI. As one would expect, CgA was also associated with 
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serum creatinine, BUN and plasma glucose. We have not found any association with bilirubin or 
liver enzymes, but previous studies have demonstrated increased CgA only in patients with liver 
cirrhosis and concomitant hepatocellular carcinoma a clinical confounder that as a relevant 
differential diagnosis to NEN disease can easily be ruled out in clinical settings [32].  
Since CgA has a protective effect on endothelial cells and it furthermore counteracts some 
effects of proinflammatory cytokines, the association between the CgA and biochemical markers 
of systemic inflammation is not surprising. Both infectious and noninfectious diseases are 
associated with increased RDW, ESR, decreased hemoglobin, albumins and thrombocyte count 
[33-37], which is in accordance with our study results.  
However, we found some novel interesting associations. For instance, the strongest correlation of 
CgA was the one with urinary phosphate, although the urinary phosphate levels were available 
only in small number of patients. This association could be explained by the presence of renal 
failure, which is associated with decreased urinary phosphorus levels [38]. Moreover, it might be 
associated with the degree of vitamin D deficiency, which correlates with severity of the 
underlying disease [39]. Unfortunately, vitamin D status was available for only 5 patients and 
therefore it has not been analyzed in our study. We also found very good correlation between 
CgA and urinary leucocytes and erythrocytes, which might also reflect the degree of chronic 
kidney disease, but may also suggest the presence of urinary tract infection, both of which may 
be associated with increased serum CgA. Finally, the last and previously non-reported 
association found in our study, is the positive correlation between alpha2-macroglobulin and 
CgA. Increased alpha2-macroglobulin is found in patients with nephritic syndrome, liver failure 
and diabetes [40], all of which are known to be associated with increased serum CgA.  
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The association between a CgA elevation and numerous confounding parameters suggests a 
relevant heterogeneity among the control subjects of the study cohort, which is an important 
advantage of our study. Hence, CgA-score has encompassed a wide range of comorbidities that 
may be encountered in everyday clinical practice. These comorbidities have been included into a 
scoring system which uses routine biochemical parameters available world-wide. Thus, 
application of our CgA-score in a given clinical situation puts each patient into a different 
interval, in which CgA has different diagnostic accuracy. We demonstrated that the CgA does 
not have any diagnostic accuracy in patients with CgA score >12. This may be very useful in 
patients with high serum CgA levels in the absence of malignant disease, in order to avoid costly 
and often invasive and harmful diagnostic procedures particularly in health care systems with 
significant financial limitations [41]. On the other hand, it can enhance the detection of NENs in 
some patients, while the early diagnosis may improve treatment outcomes. We observed several 
interesting findings in a subgroup analysis that divided patients in five intervals. CgA had the 
best diagnostic accuracy in subjects in I1, as might be expected.  These subjects do not have 
significant comorbidities that would influence serum CgA levels. Further, the diagnostic 
accuracy of similar serum CgA cut-off was slightly lower in I2, but still higher than reported in 
the entire study population. However, when subdividing patients with CgA score >12, we came 
to unexpected results. In subjects categorized into I3 interval, CgA did not have any diagnostic 
accuracy, probably due to substantial comorbidities leading to falsely increased CgA levels. 
Moreover, the presence of metastatic disease was the lowest in I3 interval, which could also 
explain poor diagnostic performance in this subgroup of patients. When we performed a 
subgroup analysis that included only patients with localized NENs, diagnostic accuracy slightly 
decreased in I1 and I2, while CgA did not have any diagnostic accuracy in I3, I4 and I5. This is 
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in accordance with previously mentioned explanation why CgA had no diagnostic accuracy in I3. 
Surprisingly, the diagnostic performance of CgA increased in I4 subgroup, but with two times 
higher cut-off for serum CgA level (310 μg/L in I4 vs. 150 μg/L in I1 and I2). This phenomenon 
may be explained by the fact that both patients with NENs and controls have similar 
comorbidities and similar CgA-score. Patients with NENs in I4 are patients who have significant 
comorbidities, so it makes sense that they have higher CgA cut-off. This observation also 
emphasizes the role of CgA-score for quantify the impact of comorbidities in the following way: 
one should not compare patients with NENs without comorbidities and patients without NENs 
but with comorbidities. However, it seems feasible to use serum CgA in patients with similar 
burden of comorbidities, but with a different serum CgA cut-off. Although the serum neuron-
specific enolase (NSE) is routinely used as a biomarker in patients with G3 NENs, serum CgA 
levels were similar between patients with G2 and G3 NENs in our study. We have tried to 
explain this observation with an assumption that patients with G3 NENs have rapidly progressive 
disease, which could lead to more pronounced systemic inflammatory response that might 
explain increase in serum CgA. Indeed, patients with G3 NENs had almost two times higher 
CgA-score than patients with G2 NENs. However, patients with G1 and G3 NENs had similar 
CgA-score indicating the same burden of comorbidities between these two groups, arguing 
against our previously mentioned theory. Relatively good diagnostic performance of serum CgA 
in patients with G3 NENs was reported in previous studies as well [42,43]. However, in the 
context of heterogeneity of patients with G3 NENs, the role of serum CgA as a biomarker in this 
subgroup of patients needs further assessment. 
Nevertheless, our study showed the superiority of CgA-score over the standard assessment of 
comorbidities associated with increased CgA. Interestingly, in patients who had no previously 
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defined comorbidities, the diagnostic accuracy of CgA in detecting patients with NENs 
decreased (Figure 3). This highlights two important things which must be taken into 
consideration when discussing falsely elevated CgA levels: i) there are far more diseases 
associated with increased CgA than we are currently aware of; ii) the stage of the disease is more 
important than the presence of the disease itself. CgA-score has taken into consideration both 
premises and consequently increased the diagnostic accuracy of CgA.      
Our study has several limitations and the results of this study should not be used in everyday 
clinical practice. Retrospective design, selection bias of the cohort and limited number of 
laboratory test decrease the power of this study. Larger sample size of both controls and patients 
ideally in a multi-centric setting would certainly overcome these limitations. This would also 
allow multivariate analysis, which could potentially reduce the number of parameters in CgA-
score. Moreover, larger sample size of patients with NENs would allow subgroup analyses 
regarding stage, grade and primary site of NENs. Finally, CgA-score performance should be 
validated in a different cohort of patients. However, this is a first “proof of concept” study that 
assessed the possibility for quantifying the burden of comorbidities in relation to serum CgA 
levels, which may improve the design of future validation studies.  
In conclusion, this study has demonstrated a novel scoring system that encompasses a wide range 
of comorbidities that influence serum CgA levels and could serve in a daily routine practice. 
CgA-score stratifies each subject into a certain category, in which CgA has different diagnostic 
performance in detecting patients with NENs. In our study population, CgA-score delineated 
almost 70% of the study population with increased diagnostic performance of serum CgA and 
showed the superiority over the standard assessment of comorbidities associated with increased 
CgA. It may also offer a cost-efficient alternative to molecular analysis-based test for health care 
19 
 
systems with restricted resources.  However, its application to everyday clinical practice needs to 
be evaluated. 
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Table 1. Characteristics of the study population 
 Control group 
N = 160 
NENs 
N = 55 
Age (years) 54 (39 – 64) 61 (45 – 72) 
Male gender n(%) 68 (42.5) 29 (52.7) 
Increased CgA n(%) 66 (41.2) 36 (65.5) † 
NEN disease stage n(%)     
Localized disease  N/A 28 (51.0) 
Locoregional n(%)  N/A 8 (14.5) 
Liver n(%)  N/A 19 (34.5) 
WHO grade     
1  N/A 21 (42.0) 
2  N/A 15 (30.0) 
3  N/A 14 (28.0) 
Primary tumor site n(%)     
Pancreatic NENs  N/A 22  (40.0) 
Other GEP NENs  N/A 21 (38.2) 
Lung  N/A 5 (9.1) 
Other sites  N/A 3 (5.5) 
Unknown primary  N/A 4 (7.3) 
Arterial hypertension n(%) 81 (52.3) 28 (50.9) 
PPI use n(%) 52 (33.5) 19 (35.2) 
Gastritis n(%) 88 (57.1) 29 (52.7) 
Atrophic gastritis n(%) 3 (1.9) 6 (11.1) † 
Inflammatory bowel disease n(%) 5 (3.2) 3 (5.4) 
Autoimmune disease n(%) 16 (10.3) 5 (9.1) 
Infectious disease n(%) 45 (29.0) † 8 (14.5) 
Diabetes n(%) 30 (19.4) 15 (27.3) 
Heart failure n(%) 3 (1.9) 1 (1.8) 
COPD n(%) 10 (6.5) 2 (3.6) 
Liver cirrhosis n(%) 1 (0.6) 1 (1.8) 
Renal failure n(%) 12 (7.7) 4 (7.3) 
History of other malignant disease n(%) 17 (11.0) 6 (10.9) 
Other active malignant disease n(%) 26 (16.3) † 1 (2.0) 
Recent weight loss n(%) 51 (33.1) 19 (36.5) 
Smoking status n(%) 30 (20.3) 15 (29.4) 
CgA – chromogranin A, N/A – not applicable, PPI – proton pump inhibitors, COPD – chronic 
obstructive pulmonary disease. 
† P<0.05 
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 Table 2. Correlation coefficients and receiver operating characteristic analysis showing the 
association between serum chromogranin A and other parameters, descending from strongest to 
weakest correlation coefficient.  
 Spearman 
rho 
P No of 
subjects 
Cut-off value AUC ± SE Z- statistic Score 
Urinary phosphorus -.603 0.002 24 ≤17.3 mmol/d 0.771±0.102 2.664  
Urinary leukocytes .338 <0.001 125 Present 0.597±0.038 2.528  
Hemoglobin -.315 <0.001 155 ≤126 g/L 0.645±0.045 3.186  3.2 
BUN .307 <0.001 148 >7.5 mmol/L 0.618±0.049 2.431  2.4 
Albumins -.306 <0.001 140 ≤39.74 g/L 0.683±0.046 3.942  3.9 
Alfa2 globulins .281 0.001 140 >6.83 g/L 0.642±0.048 2.971  3.0 
Body mass -.259 0.014 89 ≤75 kg 0.647±0.059 2.502  
Renal failure .257* <0.001 155 Present 0.566±0.024 2.758  2.8 
ESR .255 0.015 90 >24 s 0.631±0.061 2.139  
RDW .251 0.002 155 >13.6 % 0.653±0.044 3.468  3.5 
Thrombocytes -.248 0.002 155 ≤204∙109 /L 0.634±0.045 2.957  3.0 
Creatinine .204 0.011 154 >102 μmol/L 0.621±0.048 2.549  2.6 
PPI use .169* 0.010 155 Present 0.609±0.039 2.812  2.8 
Plasma glucose .162 0.046 152 >4.96 mmol/L 0.597±0.046 2.096  2.1 
Diabetes .143* 0.016 155 Present NS   
Hypertension .107* 0.012 155 Present 0.580±0.040 1.985  2.0 
Urinary erythrocytes .101*  0.042 115 > 5 RBC/hpf NS   
Maximum score                31.3 
ESR – erythrocyte sedimentation rate; RDW – red-cell distribution width; PPI – proton pump 
inhibitors. * correlation coefficient obtained by Eta statistic.
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Table 3. Diagnostic performance of CgA in patients with different CgA-score intervals. 
Score (interval) < 8 (I1) 
N = 43 
8 -12 (I2) 
N = 44 
12 – 16 (I3) 
N = 41 
16 – 22 (I4) 
N = 37 
> 22 (I5) 
N = 15 
Patients with NENs n (%) 6 (14.0) 12 (27.3) 12 (29.3) 11 (29.7) 2 (13.3) 
Metastatic disease n (%) 4 (66.7) 6 (50.0) 2 (16.7) 5 (45.5) 1 (50) 
AUC (95%CI) 0.905 (0.765-1.000) 0.788 (0.599-0.977) 0.421 (0.216-0.626) 0.745 (0.564-0.929) 0.615 (0.351-0.880) 
P value <0.001 0.006 0.431 0.019 0.610 
CgA cut-off (ng/ml) 150.0 152.0 N/A 310.0 N/A 
Sensitivity (%) 66.7 (22.3-95.7) 75.0 (42.8-94.5) N/A 72.7 (39.0-94.0) N/A 
Specificity (%) 97.3 (85.8- 99.9) 86.4 (65.1-97.1) N/A 80.8 (60.6-93.4) N/A 
Positive likelihood ratio 24.7 (3.3-184.9) 5.5 (1.8 - 16.5) N/A 3.8 (1.6 - 9.0) N/A 
CgA 95% sensitivity 40.0 21.0 N/A 35.0 N/A 
CgA 95% specificity 150.0 303.0 N/A 830.0 N/A 
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Figure 1. Flow chart of patients throughout the study. 
Figure 2. Correlation between serum chromogranin A and hemoglobin (a), blood urea nitrogen 
(b), serum albumins (c), alpha2 globulins (d), red distribution width (e), thrombocytes (f), serum 
creatinine (g), fasting plasma glucose (h) and CgA-score (i). Box-plots showing the difference in 
serum CgA levels in patients divided based on the presence of chronic renal failure (j), use of 
proton pump inhibitors (k) and the presence of arterial hypertension (l).  
Figure 3. Area under the curve showing the diagnostic performance of serum CgA in subjects 
with a CgA-score < 12 (a) and > 12 (b).  
Figure 4. Area under the curve showing the diagnostic performance of CgA in subjects with 
CgA-score in I1 (a), I2 (b), I3 (c), I4 (d), I5 (e) and the entire study population regardless of 
CgA-score (f). 
Figure 5. Change in diagnostic accuracy of CgA in each subgroup defined by the number of 
comorbidities (black) and CgA-score (grey)
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